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INTRODUCTION 
Diabetes mellitus is characterised by chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism resulting from 
defects in insulin secretion, insulin action or both. When fully expressed, 
diabetes is characterized by fasting hyperglycaemia but when less overt    
is recognized by glucose intolerance.1 
Diabetes is known to effect different organs in the body especially 
the eyes, kidneys, heart & nerves. It is these microvascular and 
macrovascular complications which are most troublesome. 
Diabetes has emerged as a major healthcare problem in India with an 
estimated 50.7 million diabetics2 according to data published by 
international diabetic federation (2nd only to China2) and it being predicted 
to increase to 79.43 million people by the year 2030. It is estimated that    
by 2030 every fifth person with diabetes will be an Indian4. Due to these 
sheer numbers, the economic burden due to diabetes in India is amongst 
the highest in the world. The real burden of the disease is however due to 
its associated complications which lead to increased morbidity and 
mortality. WHO estimates that diabetes, heart disease and stroke together 
will cost about $ 333.6 billion over the next 10 years in India4. 
  
 
 
Neuropathy is one of the earliest and most common chronic 
complications of diabetes5. For some patients, the condition is simply an 
annoyance and results in occasional numbness and tingling here and there. 
But neuropathy can forebode infection, loss of a limb, and even death as a 
result of peripheral neuropathy and vascular disease, and dangerous 
disturbances in blood pressure, nutrition, and urinary tract function. It can 
also be a source of heartbreak, since, in conjunction with peripheral 
vascular disease, it causes impotence and incontinence. Thus, diabetic 
neuropathy can affect a wide spectrum of systems with varying degrees of 
severity.  
Because of this it is imperative that we understand the prevalence as 
well as risk factors for diabetic neuropathy in different stages of glucose 
tolerance so that appropriate steps may be adopted for early diagnosis, 
treatment and prevention of complications. 
The present work is a modest endeavour to find the prevalence of 
neuropathy in our population and find the risk factors associated with it. 
 
 
 
 
  
 
 
AIM & OBJECTIVES 
 
1) To determine the prevalence of peripheral neuropathy in newly 
diagnosed drug naive type 2 diabetes mellitus. 
 
2) To determine the prevalence of peripheral neuropathy in impaired 
glucose tolerance patients. 
 
3) To determine the risk factors for the same in the above mentioned 
populations 
 
 
 
 
 
 
 
 
 
 
                          
  
 
 
DIABETES MELLITUS 
                                Diabetes mellitus is a group of metabolic 
disorders characterized by chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or 
both. 
                                    HISTORY 
The history of diabetes is as old as that of medicine. Early 
evidence of description of symptoms of diabetes has been 
recorded in the Ebers papyrus, 1550 BC 6. Arateus (30-90AD) 
coined the term diabetes, meaning ―siphon‖ to explain the 
―liquefaction of flesh and bones into urine‖. In Greek it means 
―to run through‖ that describes the ―unquenchable thirst‖ seen in 
association with this disease7. Shushruta (Circa 600 AD) noted 
this disease in Ayurveda and described it as ―madhumeha‖ 8. 
In 1869, Paul Langerhans, in his dissertation on pancreatic 
histology described ―clumps of cells‖ which were named the 
islets of langerhans shortly after his death9,  10. In 1889, 
Minkowski and Von Mering, in St rassburg, Germany discovered 
the central role of insulin of pancreas in diabetes 11. In 1910 Jean 
  
 
 
de Meyer suggested that the pancreatic secretion lacking in 
diabetic state be called ―insulin‖ to denote its origin from the 
insulae of Langerhans12. Banting and Charles Best in 1921, 
extracted insulin from dogs‘ pancreas 13.The first chemical 
application of insulin was on a 14yr old boy, Leon Thompson, a 
patient with diabetic ketoacidosis in January 1922 Canada. This 
revolutionized the management of diabetes mellitus. Oral 
hypoglycaemic drugs were introduced by Frank and Fuchs in 
19556. 
                      DIABETES AS WE KNOW IT 
  When fully expressed, diabetes is characterized by fasting 
hyperglycaemia, but the disease can also be recognized during 
less overt stages, most usually by the presence of glucose 
intolerance. Diabetes may present with characteristic symptoms 
such as thirst, polyuria, blurring of vision, weight loss, and 
polyphagia, and in its most severe forms, with ketoacidosis or 
nonketotic hyperosmolar state, which, in the absence of 
effective treatment, leads to stupor, coma and death. However 
the catch in the story of diabetes mellitus is that, 
hyperglycaemia sufficient to cause pathologic functional 
  
 
 
changes is often present for a long time before the diagnosis is 
made. 
Table- 1 CLASSIFICAITON OF DIABETES MELLITUS 1 
Type 1 (ß cell destruction, usually leading to absolute insulin deficiency) 
A. Autoimmune  
B. Idiopathic  
Type 2  (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly secretory defect 
with or without insulin resistance)  
Other specific types  
Genetic defects of β-cell function  
Genetic defects in insulin action  
Diseases of the exocrine pancreas  
Endocrinopathies  
Drug- or chemical-induced  
Infections  
Uncommon forms of immune-mediated diabetes  
Other genetic syndromes sometimes associated with diabetes  
 
                         Type 1 Diabetes mellitus 
Type 1 diabetes is the form of the disease primarily due to 
β-cell destruction. This usually leads to a type of diabetes in 
which insulin is required for survival 14. Type 1 diabetes usually 
  
 
 
is characterized by the presence of anti -GAD, anti-islet cell or 
anti-insulin antibodies, which reflects the autoimmune processes 
that have led to β-cell destruction (type 1A)15,16 . However, 
particularly in non whites, type 1 diabetes can occur in the 
absence of autoimmune antibodies and without evidence of any 
other autoimmune disorder (type 1 B or idiopathic).   
                     Type 2 Diabetes Mellitus 
Type 2 diabetes is the most common form of diabetes. 
Patients with type 2 diabetes usually have insulin resistance and 
relative, rather than absolute, insulin deficiency.  The specific 
aetiology of this form of diabetes is not known .At the time of 
diagnosis of diabetes, and often throughout their lifetimes, these 
patients do not need insulin treatment to survive, although 
ultimately many may require it for glycemic control. This form 
of diabetes is associated with progressive β -cell failure with 
increasing duration of diabetes17.Type 2 diabetes frequently 
goes undiagnosed for many years because the hyperglycaemia 
develops gradually and in the earlier stages is not severe enough 
to produce the classic symptoms of diabetes. However, such 
patients are at increased risk of developing macrovascular and 
microvascular complications.  
  
 
 
Impaired glucose tolerance 
IGT is a stage of impaired glucose regulation that is 
present in individuals whose glucose tolerance is above the 
conventional normal range but lower than the level considered 
diagnostic of diabetes . IGT cannot be defined on the basis of 
fasting glucose concentrations; an OGTT is needed to categorize 
such individuals18. Persons with IGT do have a high risk of 
developing diabetes, although not all do so. Some revert to 
normal glucose tolerance, and others continue to have IGT for 
many years. But studies have shown that most patients with 
impaired glucose tolerance move towards greater glucose 
dysequlibrium (DPP study) 19. Persons with IGT have a greater 
risk than persons of similar age with normal glucose tolerance 
of developing arterial disease 20. Although initially thought not 
to be associated with microvascular complications recent studies 
show significant prevalence19. 
Impaired fasting glucose 
IFG is also a stage of impaired glucose homeostasis. This 
category was introduced in the 1997 ADA and 1999 WHO 
classifications15,  16 to include individuals whose fasting glucose 
levels were above normal but below those diagnostic for 
  
 
 
diabetes. If an OGTT is performed, some of these individuals 
will have IGT and some may have diabetes. Consequently, it is 
prudent, and recommended by WHO, that such individuals, if 
possible, have an OGTT to exclude diabetes. Although both 
categories contain individuals with a high risk of progressing to 
type 2 diabetes20,21 ,22 ,23  the proportion with IFG in most 
populations is smaller than that with IGT. 24 
Criteria for the diagnosis of Diabetes Mellitus*25,26,27 
(1) HbA1C ≥ 6.5% or  
(2) Fasting plasma glucose > 126 mg/dl or 
(3) 2-hr plasma glucose > 200 mg/dl post 75g oral glucose challenge or 
(4) Random plasma glucose > 200 mg/dl with symptoms (polyuria, 
polydypsia, and unexplained weight loss) 
*For criteria 1-3: Repeat test to confirm unless symptoms are present. It is 
preferable that the same test be repeated for confirmation. If two different 
tests are used (e.g., FPG and A1C) and both indicate diabetes, consider the 
diagnosis confirmed. If the two different tests are discordant, repeat the test 
above the diagnostic cut point. 
Criteria for Pre-diabetes**25,26,27 
(1) Fasting plasma glucose 100 – 125 mg/dl [Impaired fasting glucose 
(IFG)] or 
  
 
 
(2) 2-hr post 75g oral glucose challenge 140 – 199 mg/dl [Impaired glucose 
tolerance (IGT)] or  
(3) HbA1C 5.7 % – 6.4 %  
**For all tests, risk of diabetes is continuous, extending below the lower 
limit of the range and becoming disproportionately greater at higher ends 
of the range. 
Screening for Diabetes Mellitus- 
Consider screening for diabetes mellitus in any adult with BMI ≥ 25 with 1 
or more risk factors for diabetes. Otherwise start at the age of 45(if normal 
repeat testing every 3yrs). 
Monitor for diabetes development annually in all pre diabetics. 
 Use risk factor analysis: Screen for overt diabetes in high risk patients, 
pregnant women in early pregnancy, prior GDM, prior delivery of LGA 
baby, PCOS, glucosuria, strong family history of type 2 diabetes mellitus.   
Screening for Diabetic Neuropathy 
At diagnosis and annually 
Feet examination every three months. 
                  
 
 
 
  
 
 
DIABETES AND NERVOUS SYSTEM 
   ―The era of coma has given way to the era of complications.‖ 
                                                                                         —Elliot P. Joslin 
Of all the long-term complications of diabetes, none affects so many 
organs or systems of the human body as the group of conditions that are 
included under the term diabetic neuropathies. The frequency with which 
diabetes affects the nervous system and the diverse manifestations might 
well explain the belief till the middle of the 19th centuary28 that diabetes 
was the consequence rather than the cause of nerve dysfunction.  
Peripheral neuropathies have been described in patients with primary 
(type 1 and type 2) and secondary diabetes of differing causes, suggesting a 
common etiologic mechanism based on chronic hyperglycaemia. The 
pivotal role of hyperglycaemia in the pathogenesis of neuropathy has 
received strong support from landmark studies such as the Diabetes 
Control and Complications Trial (DCCT) 29, 30 and the United Kingdom 
Prospective Diabetes Study (UKPDS)31.. Neuropathies are characterized by 
a progressive loss of nerve fibres that can be assessed noninvasively by a 
variety of methods, varying from a structured neurologic examination 
through quantitative sensory testing to detailed electrophysiology (EP) and 
autonomic function testing.32  
    
  
 
 
HISTORY 
The first clinical description of diabetic peripheral neuropathy was 
given by Rollo in 1798, when he described the paraesthesias and pain in 
the foot of a diabetic patient. However  it was Marchal de Calvi in France 
who recognized the true nature of the condition in 1864.33, Later, Charcot 
extended these observations as well as described (initially in syphilis) the 
neuroarthropathy which has  now come to be named after him.34 Davies-
Pryce, a surgeon working in Nottingham, England, was the first to 
recognize the link between diabetic neuropathy and foot ulceration.35 It was 
not until the twentieth century, however, that autonomic neuropathy in 
diabetes was first reported.36 
 
DEFINITIONS AND CLASSIFICATION 
Although there have been previous classifications based on 
pathologic and etiologic considerations, it has become increasingly clear 
that, causative mechanisms resulting in neuropathy are multiple and 
complex. So a clinical or descriptive classification of the neuropathies is 
favoured.32, 37. Even in this area, a number of classifications exist. 
Examples include the purely clinical descriptive classification proposed by 
Boulton and Ward38 and that based on potential reversibility together with 
clinical description 32, 39 
 
  
 
 
Descriptive Clinical Classification of Diabetic Neuropathies (Table-2)38 
Poly neuropathy Mononeuropathy  
Sensory -             Acute sensory 
                           Chronic sensorimotor 
Autonomic 
Proximal motor 
Truncal  
Cranial  
Isolated peripheral 
Mononeuritis multiplex 
Truncal  
 
Classification Based on Potential Reversibility (Table – 3) 39,40 
 Rapidly reversible :       Hyperglycaemic neuropathy 
 
Persistent symmetrical :  Sensorimotor (Chronic) 
                                       Acute Sensory 
                                       Autonomic  
 
Focal and multifocal :      Cranial 
                                        Thoracoabdominal radiculopathies 
                                        Focal limb 
                                        Amyotrophy (Proximal motor) 
                                        Compression/entrapment 
 
Superimposed Chronic Inflammatory Demyelinating Polyneuroapthy 
(CIDP) 
   
  
 
 
The San Antonio consensus defined diabetic neuropathy as ―a 
demonstrable disorder clinically evident or subclinical, occurring in the 
setting of diabetes without non diabetic causes, including manifestations in 
the somatic and/or autonomic parts of the peripheral nervous system.‖41, 
The Rochester Diabetic Neuropathy Study established a paradigm for 
clinical trial design.42,43. The following were assessed: (1) neuropathic 
symptoms (neuropathy symptom score, NSS), (2) neuropathic deficits 
(neuropathy impairment score), (3) sensorimotor nerve conduction 
velocity, (4) quantitative sensory tests, and (5) autonomic function tests. 
The minimum criteria for a diagnosis of neuropathy required two or more 
abnormalities among the listed criteria. Staging was as follows: N0 = no 
neuropathy, minimum criteria unfulfilled; N1 = asymptomatic neuropathy 
(NSS = 0); N2 = symptomatic neuropathy; N3 = disabling neuropathy. 
 
EPIDEMIOLOGY 
The quality and even quantity of epidemiologic data on diabetic 
neuropathy remain poor for a number of reasons, including inconsistent 
definitions, poor ascertainment, lack of population based studies, and 
failure to exclude non diabetic neurologic disease32,37,44. The available data 
show a wide variation in the prevalence of diabetic neuropathy. The 
population-based studies (western) showed a high prevalence, suggesting 
that at least half of older, type 2 diabetic patients had significant 
  
 
 
neuropathic deficits and hence were at high risk for insensitive foot 
ulceration.45.However neuropathy may be present at diagnosis in type 2 
diabetes. The prevalence was 4-6 times greater in clinically newly 
diagnosed diabetic subjects (14-43%) compared to normal people 46,47.48. 
More disturbing than this is the increasingly reported data regarding the 
prevalence of neuropathy in patients with impaired glucose tolerance 
suggesting that neuropathy begins to emerge in the prediabetic stage. The 
lack of longitudinal studies makes this increased prevalence in IGT patients 
controversial. 
Table--4 
STUDY  / 
COUNTRY 
 
NORMAL 
 
NEW 
DIABETIC 
 
IGT 
 
KNOWN 
DIABETIC 
Ratzmann et al 46  14.7%   
Partenan et al47 2% 8%   
Franklin (SLV)49 3.5%  11.2%  
Hoorn48 .5% 16% 43.3% 68.5% 
Young et al (UK)50    28.5% 
*Dyck et al (US)42    47.6% 
*Kumar et al(UK)45    41.6% 
*Zeigler et GER)51    28% 
Pradeepa et al52  19.5%  27.8% 
 
  
 
 
Certain prospective studies have assessed risk factors for the 
development of neuropathy. The DCCT and UKPDS demonstrated a clear 
relationship between poor glycemic control and the development of 
neuropathy. In addition to glycemic control, Adler and co-workers 53  
identified height, age, and alcohol intake as significant risk factors for 
neuropathy in a study of U.S.Veterans. Other studies have identified 
ischemic heart disease, smoking, and diabetes duration as being 
independently related to neuropathy 54. In the Eurodiab prospective study, 
in addition to hyperglycaemia, independent risk factors that predicted the 
development of neuropathy included BMI, hypertension and deranged 
lipids.55 
CLINICAL FEATURES 
Focal and Multifocal Neuropathies 
A number of characteristic focal and multifocal neuropathies, none of 
which are unique to the diabetic patient, occur in diabetes; together, they 
account for no more than 10% of all the neuropathies. Most of these tend to 
occur in older, type 2 patients and is often painful but the prognosis is 
generally good with the patients making complete or partial recovery. The 
rapid onset of symptoms and signs in most cases, together with the focal 
nature of the deficits, is suggestive of a vascular aetiology.  
 
  
 
 
Cranial Mononeuropathies - Diabetic ophthalmoplegia (third nerve 
palsy) is the commonest, and may be of relatively rapid onset, presenting  
with pain in the orbit, diplopia, and ptosis. It may also involve the the 5th 
and the 4th cranial nerves.  
Isolated and Multiple Mononeuropathies - A number of nerves are prone 
to pressure damage in diabetes; by far the most common is the median 
nerve as it passes under the flexor retinaculum resulting in carpal tunnel 
syndrome (CTS). In the Rochester Diabetic Neuropathy Study, 30% of 
patients had EP evidence of median nerve compression, although only 
fewer than 10% had characteristic symptoms42. Other, less frequently seen 
entrapment neuropathies may involve the ulnar nerve, the lateral cutaneous 
nerve of the thigh (meralgia paresthetica), the radial nerve (wrist drop), and 
the peroneal nerve (foot drop). Occurring in isolation, most of the above 
(except foot drop) carry a good prognosis with recovery, although surgical 
decompression may be required. Mononeuritis multiplex simply describes 
the occurrence of more than one isolated mononeuropathy in an individual 
patient. 
Truncal Neuropathies -  Truncal neuropathy is typically characterized by 
pain occurring in a dermatomal band like distribution around the chest or 
abdomen. The pain may be severe and have the characteristics of both 
nerve trunk pain and dysesthesias. Thus, the patient may experience dull, 
aching, boring pain together with burning discomfort or allodynia. EP 
  
 
 
investigation, including needle electrode electromyography, is useful and 
can be diagnostic. Truncal neuropathies may occasionally present with 
motor manifestations, typically a unilateral bulging of abdominal muscles 
that is usually associated with pain as described56. Prognosis is good and 
recovery is the rule. 
Proximal Motor Neuropathy -Typically affecting older, male, type 2 
diabetic patients, proximal motor neuropathy (amyotrophy) presents with 
pain, wasting, and weakness in the proximal muscles of the lower limbs, 
either unilaterally or with asymmetrical bilateral involvement. In addition, 
there is often a distal symmetrical sensory neuropathy, and weight loss of 
as much as 40% of premorbid body mass may occur.57 Buckling of knees 
and difficulty in climbing stairs are typical symptoms. The aetiology of 
diabetic amyotrophy is probably a polyradiculopathy. Recovery is gradual. 
Chronic Inflammatory Demyelinating Polyneuropathy - A 
demyelinating neuropathy meeting the electrophysiologic criteria for 
chronic inflammatory demyelinating  polyneuropathy (CIDP) has been 
increasingly recognized to occur more commonly in patients with both type 
1 and type 2 diabetes.58 The clinical picture is of a symmetrical, 
predominantly motor polyneuropathy with proximal and distal weakness in 
the lower limbs with reduced reflexes that has a progressive course. 
Because patients with CIDP might respond to immunomodulatory therapy, 
  
 
 
it is important to distinguish this condition from other diabetic 
neuropathies, particularly proximal motor neuropathy. Therefore, CIDP 
should be suspected in neuropathic diabetic patients in the following cases: 
1. A predominance of motor signs involving proximal or distal lower limb 
muscles.2. After some years of distal sensory neuropathy, a motor 
neuropathy develops with progressive symptoms and signs. 3. A patient is 
diagnosed with proximal motor neuropathy (amyotrophy).  
Symmetrical Neuropathies 
Autonomic Neuropathy – The autonomic nervous system, which controls 
a wide range of bodily functions, can be damaged in diabetes with a variety 
of manifestations, most commonly cardiovascular, urogenital, 
gastrointestinal, thermoregulatory, and sudomotor function.59  
Cardiovascular - Cardiac autonomic neuropathy manifests initially as an 
increase in heart rate secondary to vagal denervation followed by a 
decrease due to sympathetic denervation; finally, a fixed heart rate 
supervenes, which responds only minimally to physiologic stimuli. 
Postural hypotension is common due to efferent sympathetic denervation.  
Gastrointestinal - Autonomic neuropathy of the gastrointestinal system 
manifests as an abnormality in motility, secretion, and absorption. 
Clinically, patients present with two major problems: diabetic 
gastroparesis, manifested by nausea, postprandial vomiting, and alternating 
  
 
 
nocturnal diarrhea and constipation.59 The diagnosis and treatment of these 
abnormalities represent an extremely difficulty. 
Erectile Dysfunction - ED resulting from autonomic dysfunction is 
usually progressive but of gradual onset and progression.59.The patients 
may also have retrograde ejaculation. 
Bladder Dysfunction - Bladder dysfunction is also well recognized as a 
consequence of autonomic neuropathy in some patients; this ―cystopathy‖ 
is usually the result of neurogenic detrusor muscle abnormality. In extreme 
cases, gross bladder distension may occur with abdominal distension and 
overflow incontinence. 
Sweating Abnormalities - Abnormalities of sweating are common but 
often neglected60. Most common is reduced sweating in the extremities, 
particularly the feet, which is a manifestation of sympathetic dysfunction. 
In contrast to the dry feet, some patients complain of drenching truncal 
sweating, particularly at night. Gustatory sweating, which is profuse 
sweating in the head and neck region on eating certain foods, is a highly 
characteristic symptom of diabetic autonomic neuropathy that is also 
common in patients with nephropathy and is ―cured‖ by renal 
transplantation.61   
Distal Sensory Neuropathy Distal sensory neuropathy is the most 
common of all the diabetic neuropathies. It is a diffuse symmetrical 
disorder, mainly affecting the hands and legs in a glove and stocking 
  
 
 
distribution. It is often accompanied by motor symptoms (sensorimotor 
neuropathy). 
The onset of sensory neuropathy is insidious and symptoms that may 
be intermittent in the early stages. However, some patients have a rapid 
onset of painful symptoms. This latter type,  often follows a period of 
severe metabolic instability (hyperglycaemic neuropathy) or may be 
precipitated by a sudden improvement of control (―insulin neuritis‖),62 The 
symptoms in this type are usually severe, whereas there may be few if any 
clinical signs, and quantitative testing may be normal.  
  The neuropathic symptoms may be difficult for the patient to 
describe but typically fall into a recognizable pattern, ranging from the 
severely painful (or positive) at one extreme, with burning pain, stabbing, 
and shooting sensations; uncomfortable temperature sensations; 
paraesthesias, hyperaesthesias, and allodynia; to mild or ―negative 
symptoms,‖ such as decreased pain sensation, deadness, and numbness. 
Symptoms fluctuate with time and are prone to nocturnal exacerbation with 
bedclothes hyperesthesia. Another relatively common complaint in 
neuropathy is that of postural instability; diabetic neuropathic patients 
report more falls, and unsteadiness (secondary to disturbances in 
proprioception). Although neuropathic symptoms are predominantly if not 
exclusively sensory, in many cases the signs are both sensory and motor, 
with sensory loss in a stocking distribution, together with minor degrees of 
  
 
 
small muscle wasting and occasionally weakness. The ankle reflex is 
usually reduced or absent. Because some neuropathic patients may be 
asymptomatic, it is essential that all diabetic patients have their feet 
examined on a regular basis.37 
Small-Fibre Neuropathy - This shares many similarities with the acute 
sensory neuropathy, but symptoms tend to be more persistent. However, 
this may simply represent an early stage in the development of chronic 
sensorimotor neuropathy.63. Recently, a similar predominantly small-fiber 
neuropathy often with severe painful symptoms, has been observed in 
patients with Impaired Glucose Tolerance (IGT64). The patients with IGT 
may also have features of large fibre involvement. 
PATHOGENESIS 
The pathogenesis of peripheral neuropathy is complex and involves the 
interaction of several factors. Given below is a brief discussion of the 
contributing factors. 
Hyperglycaemia 
In type 2 diabetes, longitudinal data from the Rochester cohort 
supports the contention that the duration and severity of exposure to 
hyperglycemia are related to the severity rather than the onset of 
neuropathy.65 Studies in patients presenting with symptoms of a small fibre 
neuropathy suggest an increased prevalence of impaired glucose tolerance 
(IGT) in these patients, suggesting a glycemic threshold below the current 
  
 
 
definition of diabetes above which polyneuropathy develops66.  However, 
in a recent population based study the prevalence of polyneuropathy was 
28.0% in diabetic subjects and only 13.0% in those with IGT, 11.3% in 
those with impaired fasting glucose (IFG) compared to 7.4% in those with 
normal glucose tolerance (NGT), indicating a minimal contribution of 
hyperglycemia.67 This may indicate that other factors other than 
hyperglycaemia may contribute to the pathogenesis. With regard to the 
effects of intervention, the data supportive of benefit with improving 
glycemic control is controversial. While the UKPDS and the DCCT study 
showed improvement and blunted progression of neuropathy with glycemic 
control, the VA cooperative study in type 2 diabetic patients, 153 patients 
who were randomized to intensive versus conventional therapy achieved a 
2.07% difference in HbA1c over 2 years but failed to demonstrate a 
significant difference in the progression of either somatic or autonomic 
neuropathy.68 Similarly, the Steno-2 study which implemented 
multifactorial intervention, including improved glycemic control, improved 
autonomic but not somatic neuropathy69,70. 
Polyol Pathway Abnormalities 
The excess glucose is metabolised by aldose reductase to form 
sorbitol and the latter by the action of sorbitol dehydrogebnase is converted 
to fructose. The excess sorbitol decreases the intracellular levels of 
  
 
 
myoinositol which in turn decreases the activity of Na- K ATPase activity. 
This results in structural and functional abnormalities of nerves71. 
Animal models of diabetes consistently demonstrate an association 
between increased flux through the polyol pathway and a reduction in 
NCV, both of which can be ameliorated with aldose reductase inhibitors 
(ARIs)72. An early meta-analysis of randomized controlled trials of ARIs, 
only demonstrated a small but statistically significant reduction in decline 
of median and peroneal motor nerve conduction velocity73. 
Glycation 
Hyperglycaemia induces the formation of advanced glycation end 
products (AGEs) on peripheral nerve myelin which contributes to 
segmental demyelination by increasing its susceptiblity to phagocytosis by 
macrophages. Also it modifies axonal cytoskeletal proteins such as tubulin, 
neurofilament, and actin resulting in axonal atrophy and degeneration but 
reduced regeneration due to glycation of laminin.74 However, in a primate 
model of type 1 diabetes, 3 years of treatment with aminoguanidine (agent 
which prevent the formation of AGE) did not restore conduction velocity 
or autonomic function75. It is becoming increasingly apparent that many 
drugs that are currently used for other indications including pioglitazone, 
metformin76, angiotensin-converting enzyme (ACE) inhibitors and ATII 
antagonists may act as powerful antiglycating agents. 
 
  
 
 
Oxidative Stress - 
A considerable body of data supports the role of oxidative stress in 
the pathogenesis of diabetic neuropathy in animal models77. AGE or 
Amadori products, reacts with receptors for AGE (RAGE). This binding 
induces a cascade of signalling events leading to the production of reactive 
oxygen species (ROS)78,79. The ROS in turn acts on the lipids forming lipid 
peroxides which are directly toxic to the cells80. On dividing cells it results 
in DNA mutations and genomic instability81. On non dividing cells like 
neurons the damage to proteins and lipids make them dysfunctional and 
unable to perform normal axonal transport and signalling 82. Hence 
increasing antioxidant potential is an attractive treatment strategy. Short 
term benefits have been observed with intravenous alpha-lipoic acid (LA), 
a powerful antioxidant that scavenges hydroxyl radicals and superoxide 
and peroxyl radicals and regenerates glutathione.83 
Poly (ADP-Ribose) Polymerase-1 (PARP) 
Increased oxidative and nitrosative stress activates the nuclear 
enzyme, poly(ADP-ribose) polymerase-1 (PARP) which depletes its 
substrate, NAD+, slowing the rate of glycolysis, electron transport, and 
ATP formation and inhibits GAPDH by poly (ADP-ribosy)lation.84 These 
lead to a deleterious effect on nitrergic (NO) innervation, contributing to 
autonomic neuropathy.  
 
  
 
 
C Peptide 
Impaired insulin/C peptide action has emerged as a prominent factor 
in the pathogenesis of the microvascular complications in type 1 diabetes. 
Experimental studies have demonstrated a range of actions that include 
effects on expression of neurotrophic factors, regulation of molecular 
mechanisms underlying the degeneration of the nodal apparatus, as well as 
DNA binding of transcription factors leading to modulation of apoptosis.80 
C-peptide has been proposed to prevent and reverse myelinated nerve 
degeneration of the node and paranode and unmyelinated nerve axonal 
degeneration, atrophy, and loss.85. 
Vascular Endothelial Growth Factor 
Vascular endothelial growth factor (VEGF) regulates angiogenesis 
and neuronal survival by stimulating neurons and glial cells to survive and 
grow. Thus, with its potential for a dual impact on both the vasculature and 
neurons, it could represent an important therapeutic intervention in diabetic 
neuropathy. To date, a therapeutic benefit in diabteic neuropathy has been 
demonstrated for VEGF in experimental studies only. 
Neurotrophins 
Neurotrophins promote the survival of specific neuronal populations 
by inducing morphologic differentiation, enhancing nerve regeneration, 
stimulating neurotransmitter expression, and altering the physiologic 
characteristics of neurons. Thus modulating neurotrophic support 
  
 
 
represents an alternative approach to the treatment of diabetic neuropathy, 
that is the stimulation of repair without necessarily addressing the 
underlying cause of nerve damage. 
Mitogen-Activated Protein Kinase 
Upstream inducers and transducers signal transcriptional and 
translational abnormalities through effector molecules referred to 
collectively as the mitogen-activated protein kinase (MAPK) family, which 
mediate early gene responses and aberrant phosphorylation of 
neurofilaments, which are major constituents of the axonal cylinder86. 
Thus, any abnormality in synthesis, delivery, or processing of these critical 
proteins could lead to impairments in axon structure and function87. 
PATHOLOGY 
Detailed morphometric studies of sural nerve biopsies provide 
considerable insights into the underlying pathology and pathogenesis of 
diabetic neuropathy. A significant abnormality in both myelinated and 
unmyelinated fibres occurs despite entirely normal clinical and 
neurophysiologic tests of neuropathy.88,89,90 
Myelinated Fibres -The hallmark of advanced diabetic neuropathy is loss 
of myelinated fibers88. 
Unmyelinated Fibres- Axonal degeneration with active regeneration of 
unmyelinated fibres occurs early in the evolution of neuropathy prior to 
axonal degeneration of the myelinated fibres,91 but importantly, their 
  
 
 
regenerative capacity is maintained long after the myelinated fibres have 
lost their capacity to regenerate 92,93 
Autonomic Tissue- Pathologic studies of autonomic tissue are limited to 
post-mortem or surgical material. In patients with diabetic gastropathy, the 
vagus nerve shows a reduction in myelinated fibre density and 
degeneration along with regeneration of unmyelinated fibres.94 
Quantitative studies have demonstrated degenerative or dystrophic changes 
in axonal and dendritic components of sympathetic ganglia in the absence 
of significant neuron loss, as well as alterations in the postganglionic 
autonomic innervation of various end organs.95 
Nerve Vasculature 
Structural abnormalities of the vessels supplying the peripheral nerve 
include arteriolar attenuation, venous distention, arteriovenous shunting, 
and new vessel formation96,97 along with intimal hyperplasia, hypertrophy98 
and denervation.99  
MEASURES OF NEUROPATHY 
The diagnosis and staging of neuropathy are important not only for 
day-to-day clinical practice, but also for the conduct of clinical protocols to 
assess its aetiology and natural history and to test new proposed treatments.  
Clinical Symptoms 
Accurate recording of symptoms is essential both for clinical 
practice and trials of new medications. The neuropathy symptom score  
  
 
 
(NSS) is a standardized list of questions and neuropathic symptoms that is 
applied by a trained individual in a standardized manner. A simplified NSS 
has been used for epidemiologic studies and can be applied in clinical 
practice,22,27,50,100 
Table- 5101 
 Diabetic Neuropathy symptom score: 
1 point for each positive response 
Unsteadiness of gait 
Pain/burning/aching of feet 
Prickling sensation of feet/legs 
Numbness feet  
 
Clinical Signs 
For assessing clinical signs, two simple instruments can be used in 
clinical practice, First102 the Michigan Neuropathy Screening Instrument 
(MNSI); this two-step program is used for diagnosis and staging of 
neuropathy. The MNSI consists of a 15-question yes/no symptom 
questionnaire that is supplemented by a simple clinical examination. 
Patients with an abnormal score on the MNSI are then referred for QSTs 
and EP. Second, the simplified neuropathy disability score (NDS) 103 is a 
simple clinical examination that sums abnormalities of reflexes and  
  
 
 
MICHIGAN NEUROPATHY SCREENING 
INSTRUMENT 
  
 
 
• Are your feet numb 
 
• Burning pain 
 
• Feet sensitive to the 
touch 
 
• Able to sense feet 
when walking 
 
• Can you tell hot from 
cold water 
 
• Have you had an ulcer 
 
• Doctor-diagnosed 
neuropathy 
 
• Do you feel weak 
  
 
• Symptoms worse at 
night 
 
• Do legs hurt when you 
walk 
 
• Prickling feeling 
 
• Muscle cramp 
 
• Bed covers hurt your 
skin 
 
• Does skin crack open 
 
• Have you had an 
amputation 
  
 
 
 
sensory assessment; it has been used in clinical practice and epidemiologic 
studies. 
  
Neurology Deficit Score103 is calculated as follows: 
Table- 6 
         Vibration perception                                 
Temperature perception 
Pin prick 
Normal =0  Abnormal =1 
Achilles Reflex - present =0,present with reinforcement=1 absent =2 
 
Quantitative Sensory Testing 
QST‘s assess the patient‘s ability to detect a number of sensory 
stimuli and have the advantage that they directly assess the degree of 
sensory loss at the most vulnerable site: the foot. Some of the more 
commonly used techniques are now briefly discussed. 
Semmes-Weinstein Monofilaments 
Semmes-Weinstein monofilaments comprise sets of nylon filaments 
of variable diameter that buckle at a predefined force when applied to the 
  
 
 
testing site. They are widely used in clinical practice and are particularly 
helpful in the identification of subjects who are at risk of neuropathic foot 
ulceration. Inability to perceive pressure of a 10-g monofilament has been 
shown in prospective studies to predict risk of neuropathic ulceration.104 
Vibration Perception 
Vibration perception thresholds (VPTs) test large myelinated fibre 
function. VPT increases with age in normal individuals and also tends to be 
higher in the lower extremities. Vibration of increasing intensity is applied 
using a biothesiometer. An abnormal reading greater than 25 V has been 
associated with a high risk of foot ulceration 105,56. 
Thermal and Cooling Thresholds 
Warm and cold sensation is transmitted via small myelinated and 
unmyelinated fibres and can be assessed by using a number of devices. 
However, they remain the most variable of all QSTs. 
Computer-Assisted Sensory Examination 
This complex methodology is currently regarded as state of the art 
for clinical trials and is a computerized device that can measure touch-
pressure, vibration, and warm-cold thresholds using a forced-choice 
algorithm.  
Autonomic Function Testing 
Cardiovascular autonomic dysfunction can be evaluated in detail by 
employing Ewing and Clarke‘s battery of five tests: (1) the average 
  
 
 
inspiratory-expiratory heart rate difference with six deep breaths, (2) the 
Valsalva ratio, (3) the 30:15 ratio, (4) the diastolic blood pressure response 
to isometric exercise, and (5) the systolic blood pressure fall to 
standing106,107,42,48 . 
Electrophysiology 
Electrophysiological measures of nerve function have been the 
mainstay of objective assessment of presence and severity of peripheral 
nerve involvement in patients with diabetes. They are sensitive, specific 
and reproducible. Studies are typically performed in the upper limb and 
lower limb nerves108. The tests are usually done using surface electrodes109. 
The analysis of action potential relates to the total number of active fibres 
whereas conduction studies reflect the functional status of large myelinated 
sensory and motor nerve fibres. It is better at diagnosing large fibre deficits 
whereas small fibre neuropathy is poorly diagnosed.109  
Skin Biopsy  
Immunohistochemical quantification of Intraepidermal nerve fibres 
(IENF) using the panaxonal marker protein gene product 9.5 is now 
established as an early and sensitive marker of nerve damage in diabetic 
neuropathy. A significant loss of IENF has been demonstrated in patients 
with no neurological deficits and normal quantitative sensory testing as 
well as electrophysiology 110 and a reduction in IENF regenerative capacity 
  
 
 
occurs in diabetic patients111.These abnormalities are specifically seen in 
patients with painful diabetic neuropathy 112. Patients with small fibre 
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neuropathy and impaired glucose tolerance demonstrate a significant loss 
of IENF which improves with no change in QST or neurophysiology, 
suggesting that the assessment of IENF may be a more sensitive marker of 
nerve repair following therapeutic intervention113. 
Corneal confocal microscopy 
Corneal confocal microscopy represents a novel technique in vivo 
clinical examination - technique that is capable of imaging corneal nerve 
fibres. It has been shown to accurately define the extent of corneal nerve 
damage which has been related to the severity of somatic diabetic 
neuropathy114,115. It can detect small fibre neuropathy before there is 
decrease in nerve fibre density.110 
TREATMENT 
Therapies for diabetic neuropathy include those for symptomatic 
relief and those that may alter (slow) the progressive loss of nerve function 
that characterizes the natural history of neuropathy.  
Sensory Neuropathy 
Symptomatic relief - 
 Glycemic Control : Of all the treatments, tight and stable glycemic 
control is probably the only one that may provide symptomatic relief 
as well as slow the relentless progression of neuropathy.30 As it is 
probably blood glucose flux that induces neuropathic pain56, stability 
rather than the actual level of glycemic control may be most 
  
 
 
important in pain relief116. The method of achieving stable control 
does not seem to be critical; there is no evidence that insulin is 
superior if the blood glucose is well controlled by oral 
hypoglycaemic agents. 
 Risk factors for neuropathy including hypertension and hyper 
triglyceridemia should be treated. 
 Avoidance of neurotoxins like alcohol, smoking, and 
supplementation of vitamins for possible deficiencies of vitamin B12 
and folate. 
 Tricyclic Antidepressants: Until new therapies are proved to 
relieve symptoms in appropriately designed trials117, the tricyclic 
antidepressant drugs, such as amitriptyline and imipramine, will 
remain useful first-line agents for painful neuropathy in developing 
countries. The main side effects are sedation and anticholinergic 
effects like constipation, dry mouth, weight gain and orthostatic 
hypotension. These side effects are particularly problematic in the 
elderly and in them it is advisable to start on a very small dose. The 
secondary amines nortriptyline and desipramine have a 
less troublesome side- effect profile118. 
 Serotonin and noradrenaline reuptake inhibitors: The serotonin 
and noradrenaline reuptake inhibitor (SNRI) duloxetine has both 
analgesic and antidepressant effects and can be used for the 
  
 
 
treatment of diabetic peripheral neuropathic pain119. Unlike 
tricyclics, some anticonvulsants and opioids, it does not generally 
require dose titration. 
 Anticonvulsants: Carbamazepine is used in the management of 
neuropathic pain; Gabapentin 120 is also another commonly used 
agent. It binds to δ2 subunit of calcium channels on neurons. It is not 
metabolised in the body and has no drug interactions. It has a low 
side effect profile. Pregabalin is the next preferred anticonvulsant 
used. The other anticonvulsants which may also be used include 
phenytoin, lamotrigine, topiramate and tiagabine. 
 Local anaesthetic antiarrythmics—Intravenous lignocaine and its 
oral counterpart mexiletine are sodium channel antagonists which 
can be used for pain relief. They reduce the spontaneous abnormal 
and evoked discharges in damaged peripheral nerves thought to be 
responsible for pain generation. Both have been found to be 
efficacious.   
 Opiods – May be tried in the treatment of neuropathic pain in 
patients who fail to respond to adjuvant analgesics. Drugs like 
tramadol, morphine, methadone, oxycodone and levorphanol can be 
used. 
 Topical agents – Agents approved for use include caspsaicin, 
lignocaine. 
  
 
 
 Alternative therapies - Transcutaneous electrical nerve stimulation, 
neuromuscular electrical stimulation, Interferential stimulation, 
Laser therapy, Electromagnetic field therapy, Acupuncture121. 
Potential Future therapies 
 Alpha - Lipoic Acid -There is accumulating evidence to suggest that 
free radical–mediated oxidative stress is implicated in the 
pathogenesis of neuropathy. Alpha-lipoic acid, an antioxidant has 
been tried in clinical trials and has reported some benefit in 
symptoms and signs though without improvement in nerve 
conduction velocity122. 
 Aldose reductase inhibitors – They reduce the flux of glucose 
through the polyol pathway (Tolrestat, Zenarestat & Zopolrestat). In 
a randomized, placebo controlled, double-blind, multiple-dose 
clinical trial with Zenarestat, dose-dependent increments in sural 
nerve sorbitol suppression were accompanied by significant 
improvement in NCV.123. 
 γ linolenic acid124 – Essential fatty acid which is important 
constituent of neuronal membranes lipids and is a substrate for 
prostaglandin E formation which is important in maintaining nerve 
blood flow. 
 Aminogaunidine and its congeners 125- prevent formation of AGES 
  
 
 
 Protein Kinase C β inhibitors – Protein kinase C activation is a 
critical step in the pathway to the diabetic complications. 
Intracellular hyperglycaemia increases diacylglycerol levels, which 
activates protein kinase C (PKC) formation, leading to multiple 
pathogenetic consequences, including altered expression of 
endothelial nitric oxide synthetase and VEGF, However, a large 
RCT failed to demonstrate any benefit of the drug over placebo in 
measures of nerve function126. 
 Neurotropic factors 127– Decreased expression of nerve growth 
factors and its receptors reduce support of small unmyelinated 
neurons. Administration of recombinant nerve growth factors 
restores these levels to normal and decreases the manifestations of 
sensory neuropathy. 
 ACE inhibitors – ACE inhibitors have been proposed to be useful. 
A preliminary controlled study of ACE inhibitors in early 
neuropathy confirmed a significant benefit over placebo in EP 
parameters126. 
 
Autonomic Neuropathy 
 Erectile Dysfunction - Because autonomic neuropathy is one of 
several contributory causes in erectile dysfunction (ED), a 
multifaceted approach to management is indicated128,129. 
  
 
 
Psychosexual counselling and altering drug therapy to remove the 
factors associated with ED are beneficial in many cases128. 
Sildenafil, an orally active selective inhibitor of phosphodiesterase 5 
(PDE-5), is efficacious for ED in diabetic males.  
 Sweating Disorders - The first specific treatment for gustatory 
sweating has been reported. Glycopyrrolate is an antimuscarinic 
compound that, when applied topically to the affected area, results in 
a marked reduction of sweating while eating ―trigger‖ foods. Its 
efficacy was confirmed in a randomized controlled trial130. 
 Others- Treatment of diabetic gastroparesis involves measures to 
enhance gastric motility and emptying. Metoclopramide, a dopamine 
antagonist, directly stimulates antral muscle and may also mediate 
acetylcholine release. Alternative agents include domperidone, or 
erythromycin, which directly stimulates motilin receptors. 
Constipation may be treated with a combination of prokinetic agents 
such as metoclopramide and cisapride. 
 Postural hypotension may be treated with mineralocorticoids such 
as fludrocortisone, sympathomimetic agents, and dopamine blockers. 
Urinary bladder difficulties are addressed with regular voiding, self-
catheterization, and cholinergic agonists such as bethanechol 
chloride, which stimulates muscarinic, postganglionic receptors, 
enhancing bladder motility and emptying 131. 
  
 
 
 
 Foot care –Last but not the least. The feet should be examined 
everyday for bruises, cracks, dry skin, ingrown toenails, blisters or 
discolouration. Wash feet everyday using warm water and mild soap 
and apply moisturising cream to prevent the feet from being dry and 
developing cracks. Toe nails should be well maintained. Do not cut 
toe nails too short. The patients are advised to cut nails straight 
across and always check nails for sharp edges. Remove callus on a 
regular basis. Wear thick socks and well cushioned footwear which 
are big enough to cover both the feet and the sock. 
The late sequelae of diabetic neuropathy are usually considered to be 
neuropathic foot ulceration, neuroarthropathy (Charcot‘s foot), and 
amputation. 
 
 
Neuropathic Foot Ulceration 
Distal sensory and sympathetic neuropathies are the most important  
component causes that lead to foot ulceration. However, the neuropathic 
foot does not spontaneously ulcerate; typically, it is the combination of 
neuropathy with other risk factors such as deformity and unperceived 
trauma that results in ulceration. International guidelines on the clinical 
  
 
 
management of neuropathy, therefore, emphasize the importance of regular 
foot examinations and education in self-foot care in the management of 
neuropathy 
Charcot’s Neuroarthropathy 
Charcot‘s neuroarthropathy is a less common but clinically 
important and potentially devastating disorder. Permissive features for the 
development of a Charcot‘s joint include peripheral sensorimotor 
neuropathy, sympathetic denervation in the foot, and intact peripheral 
circulation; minor, unperceived trauma is often the initiating event. It is 
believed that following repetitive minor trauma, osteoblastic activity is 
stimulated with remodelling of bone. A high index of suspicion must exist 
if a neuropathic patient has unilateral unexplained swelling and warmth in 
a foot, with the possibility of infection also being kept in mind. Contrary to 
earlier texts, discomfort may be experienced, although the patient is still 
usually able to walk. Detailed assessment and investigation of such a 
patient is essential, and rest or casting of a suspected Charcot‘s foot is 
usually recommended.           
                                   IGT and Neuropathy 
IGT has come to be increasingly associated with microvascular 
complications contrary to the previous belief that it is associated with only 
arterial disease. Most patients with IGT and neuropathy have a 
symmetrical distal sensory neuropathy with prominent neuropathic pain as 
  
 
 
well as autonomic disturbances 132. Studies have shown that aggressive life 
style modification (diet and exercise) can reverse the low intraepidermal 
nerve fibre density as well as neuropathic symptoms 133.                      
MATERIALS AND METHODS 
 
Place of study   -   Department of Medicine, Govt Kilpauk Medical  
                              College, Chennai 10 
Collaborating department – Department of Diabetology, Kilpauk  
                                                 Medical College, Department of Neurology,  
                                              Kilpauk Medical College. 
Duration of study -              November 2009 - October 2110. 
Type of study  -                   Cross sectional study 
Study population – 40 patients were randomly selected in each of the 
three groups, namely newly diagnosed diabetes mellitus, impaired glucose 
tolerance and control from among patients attending the diabetic clinic, 
KMC 
Materials - Detailed questionnaire, brief clinical examination (timed 
vibration, ankle reflex & perception of pain & temperature), BMI 
calculation, BP, GTT, FBS, PPBS, Nerve conduction study, HbA1c. 
  
 
 
Inclusion criteria – 
Newly diagnosed drug naive Type 2 diabetes mellitus patients. 
Patients with impaired glucose tolerance. 
 
Patients who are euglycemic without other risk factors. 
 
Exclusion criteria – 
 
        Known type 2 diabetes mellitus 
 
        Chronic renal failure 
        Chronic alcoholics 
        Uncontrolled hypertension 
        Patients on ATT 
        Known carcinoma patients 
        Patients on drugs known to cause peripheral neuropathy. 
 
Methodology -  
 A detailed history was taken using a structured questionnaire. 
 Demographic data: Patients name, age, address, occupation, and 
information regarding socioeconomic status (modified kuppuswamy scale 
of social classification 134) was obtained. 
 Also information regarding relevant past and family history was 
obtained. 
  
 
 
 Clinical neuropathy was assessed using a questionnaire on 
neuropathic symptoms and it was analysed using diabetic neuropathy 
symptom score 101. Neuropathic pain was described as pain in the 
extremities in the absence of history of trauma and any external factors. 
Paraesthesia was defined as sensation of burning, sharpness, tingling or 
numbness. A score of 1 or more than one was considered significant. 
 Body mass index (BMI) is calculated with height and weight of the 
subject using the following formula. 
BMI= weight (kg) / height (m) 2. BMI was classified according to WHO 
criteria for Asian Population.135 
Values:     < 18.5 kg / m2 was taken as underweight. 
                      18.5 – 22.9 kg / m2 was taken as normal weight 
   23- 29.9 kg / m2 was taken as overweight. 
                    > 30 kg/m2 was taken as obesity    
 Blood pressure – Right upper arm blood pressure is taken in supine 
position by using sphygmomanometer under appropriate conditions. 
 Clinical neuropathy was assessed using a brief clinical 
examination. Timed Vibration(comparing patients‘ vibration sense with the 
examiner),pain and temperature sensation in the foot and the ankle jerk was 
examined.  Findings of the examination was assessed using Neuropathy 
  
 
 
Disability Score 103. A score of 2 or more was considered to indicate 
neuropathy. 
 Diabetes /Impaired glucose tolerance/ Normalcy was confirmed 
using FBS/PPBS/OGTT/HbA1c tests and interpreted using 2010 ADA 
criteria for the same. 
The OGTT/Oral glucose tolerance test was done in the morning after 
10-16 hours of overnight fast (water may be taken) following at least three 
days of unrestricted diet. Smoking and all physical activities were  avoided. 
At the commencement of the test a fasting blood sample is drawn. The 
subject then drinks 75g of glucose in 250 -300 ml of water. A further blood 
sample is obtained after 2 hours. Both blood samples were collected in 
fluoride oxalate tubes which prevent the red blood cells from metabolising 
glucose. 
Diabetes is diagnosed if the fasting value is ≥126 or the 2 hour plasma 
glucose is ≥ 200. 
IGT is diagnosed if the 2 hour plasma glucose is ≥140 ≤199. 
 HbA1c - Blood sample was collected in EDTA tubes and HbA1c 
was measured using HPLC method. 
 Nerve conduction study: Nerve conduction study was done using 
MEDICAID electromyography machine using surface electrodes by 
standard procedure at room temperature by trained personnel. Motor nerve 
conduction velocity (MNCV) and compound muscle action potential 
  
 
 
(CAMP) was measured in the leg segment (ankle to knee) of peroneal and 
tibial nerves on both sides. Also sensory nerve conduction velocity 
(SNCV) and sensory nerve action potential (SNAP) was recorded for both 
sural nerves in the leg segment. The values considered abnormal were as 
follows: 
Peroneal nerve – CMAP < 2mv, MNCV <42m/s 
Tibial nerve -      CMAP <3 mv, MNCV<41m/s 
Sural nerve   – SNAP < 6mv, SNCV <42m/s 
For statistical analysis the more abnormal of the 2 values for each nerve 
were taken. 
    The patient was diagnosed to have peripheral neuropathy if two of 
the three namely neuropathy symptom score, neuropathy disability score 
and nerve conduction study was abnormal (criteria by Rochester 
Diabetic Neuropathy study).   
 Statistical analysis – The results were analysed using SPSS 
software. 
The statistical tests of analysis used were 
Chi square test – for analysing discrete variables. 
Two sample ‗T‘ test- for continuous variables (2 variables)  
ANOVA test (Analysis of variance test) – for continuous variables (>2) 
variables. 
Level of significance - p= 0.05. 
  
 
 
 
  
 
 
RESULTS 
The study sample included patients each in three groups, 
 Group1- newly detected diabetes mellitus, n = 40 
 Group2- impaired glucose tolerance, n = 40 
 Group3- control, n = 40 
 
Age distribution of cases in three groups  
Table-7 
Age group Group 1 Group 2 Group 3 
20-30 1 1 3 
31-40 12 12 12 
41-50 18 17 15 
>51 9 10 10 
 
p= 0.924, not significant,  
There was no significant difference between the three groups with regard  
to age distribution 
Sex distribution of patients 
Table 8 
Sex Group 1 Group 2 Group 3 
Male 18 16 19 
Female 22 24 21 
 
p= 0.904 not significant. 
  
 
 
There was no significant difference between the three groups with regard  
to distribution of patients according to sex. 
 
Distribution of patients according to socioeconomic status134 
Table-9 
Socioeconomic 
status Group 1 Group 2 Group 3 
Low 28 25 29 
Medium 12 15 11 
 
p= 0.606, not significant. 
There was no significant difference between the three groups with regard  
to socioeconomic status. 
Distribution of patients according to past history of hypertension 
Table 10 
Hypertensive Group 1 Group 2 Group 3 
Yes 3 7 3 
No 37 33 37 
 
 p= 0.252, not significant 
There was no significant difference between the three groups with regard 
to distribution of patients according to past history of hypertension.  
None of the patients in the three groups had history of CAD/CVA/Renal 
disease.  
 
  
 
 
Distribution of patients according to history of smoking. 
Table 11 
Smoking Group 1 Group 2 Group 3 
Yes 8 10 9 
No 32 30 31 
 
p= 0.866, not significant 
There was no significant difference between the three groups with regard 
to the number of people having a history of smoking. 
 
 
Distribution of patients according to Body Mass Index (BMI) 135 
(Table-12) 
BMI(kg/m2) Group 1 Group 2 Group 3 
<18.5 0 1 0 
18.5 – 22.9 12 17 9 
23 – 29.9 26 22 28 
>30 2 0 3 
 
p= 0.645, not significant 
There was no significant difference between three groups with regard to 
BMI distribution.  
 
  
 
 
Distribution of patients according to family history of diabetes mellitus 
Table-13 
Family history of 
diabetes mellitus Group 1 Group 2 Group 3 
Yes 16 18 8 
No 24 22 32 
P=.04, significant 
There was a significant difference between the three groups with regard to  
family history of diabetes. Patients in the new diabetic as well as impaired  
glucose tolerance group has more number of patients having family history 
of diabetes compared with control group. 
Distribution of patients according to neuropathy symptom score 
(Table -14) 
  
p= 0.007, Significant.  
Neuropathy 
Symptom 
score 
Group 1 Group 2 Group 3 Total 
0 13     (32.5%) 
23     
(57.5%) 
32        
(80%) 68 (56.7%) 
1 14        (35%) 
9       
(22.5%) 
6           
(15%) 
29  
(24.2%) 
2 9       (22.5%) 
7       
(17.5%) 
2            
(5%) 
18       
(15%) 
3 3         (7.5%) 
1         
(2.5%) 
0            
(0%) 
4       
(3.3%) 
4 1         (2.5%) 
0            
(0%) 
0            
(0%) 
1      
(0.8%) 
Total 40 (100%) 
40 
(100%) 
40 
(100%) 
120 
(100) 
  
 
 
Significant symptom score (1 or more) was found in 67.5% (27) of new 
diabetics, in 42.5% (17) of IGT and in 20% of control group. 
The number of patients with neuropathic symptoms was found to be 
significantly more in new diabetic as well as IGT group when compared to 
the control group.   
 
Distribution of patients according to neuropathy disability score. 
Table 15 
Neurological 
Disability 
Score 
Group 1 Group 2 Group 3 Total 
0 26        (65%) 
30        
(75%) 
35       
(87.5%) 
91     
(75.8%) 
1 7       (17.5%) 
6          
(15%) 
5       
(12.5%) 
18        
(15%) 
2 5       (12.5%) 
4           
(10%) 
0            
(0%) 
9         
(7.5%) 
3 2            (5%) 
0            
(0%) 
0            
(0%) 
2         
(1.7%) 
Total 40 (100%) 
40 
(100%) 
40 
(100%) 
120 
(100%) 
 
p = 0.111, not significant. 
There was no significant difference in the distribution of patients according 
to neuropathy disability score in between the three groups. 
 Neuropathic disability score ≥ 2 was seen in 17.5% (7) of new diabetics, in 
10% (4) of IGT and 0% in control group. 
  
 
 
Motor nerve conduction abnormality distribution in the different 
study groups. 
Table 16 
Abnormality Group 1 Group 2 Group 3 Total 
Yes 15     (37.5%) 
14        
(35%) 
1         
(2.5%) 
30        
(25%) 
No 25      (62.5%) 
26        
(65%) 
39      
(97.5%) 
90        
(75%) 
Total 40 (100%) 
40 
(100%) 
40 
(100%) 
120 
(100%) 
 
p= 0.000, significant 
Abnormality in motor nerve conduction study was found in 37.5% of new 
diabetics, 35 % of patients with impaired glucose tolerance and in 2.5% of 
control population. The difference in distribution of cases with regard to 
motor nerve conduction abnormality between the three groups is 
statistically significant. 
  
 
 
Sensory nerve conduction abnormalities in the three groups 
Table 17 
Abnormality Group 1 Group 2 Group 3 Total 
Yes 
16       
(40%) 
12        
(30%) 
0 
(0%) 
28    
(23.3%) 
No 
24       
(60%) 
28       
(70%) 
40            
(100%) 
92        
(76.7%) 
Total 
40 
(100%) 
40 
(100%) 
40 
(100%) 
120 
(100%) 
 
p= 0.000,  significant 
Sensory nerve conduction abnormalities were found in 40% (16) of new 
diabetic group, in 30% (12) of IGT group and in 0% of control population. 
There was a significant difference in the distribution of patients in between 
the three groups with regard to sensory nerve conduction abnormality. 
Prevalence of peripheral neuropathy43 in the three groups. 
Table 18 
Neuropathy Group 1 Group 2 Group 3 Total 
Present 17 (42.5%) 
8 
(20%) 
1 
(2.5%) 
26 
(21.7%) 
Absent 23 (57.5%) 
32 
(80%) 
39 
(97.5%) 
94 
(78.3%) 
Total 40 (100%) 
40 
(100%) 
40 
(100%) 
120 
(100%) 
 
p = 0.000  significant. The prevalence of peripheral neuropathy in this 
study was found to be 42.5% among the new diabetics, to be 20% among  
  
 
 
the impaired glucose tolerant and 2.5% among the control population.  
The difference in prevalence of peripheral neuropathy between the three 
groups was found to be statistically significant. 
 
 
ANALYSIS OF RISK FACTORS 
 
GROUP 1 – NEW DIABETICS 
 
 Age vs Neuropathy 
(Table 19) 
Neuropathy Age (yrs) 
No . of. patients Mean SD 
Present 17 46.41 9.805 
Absent 23 43.57 7.867 
 
p = 0.315, not significant. The mean age of patients with neuropathy was 
46.42±9.8yrs compared to patients without neuropathy which is 43.57± 
7.8yrs . There was no significant difference in the mean age among patients 
with and without neuropathy. Age is not associated with neuropathy. 
 
 
  
 
 
 Sex   Vs neuropathy 
 
(Table 20) 
Sex Number of patients 
Neuropathy Total Present absent 
Female 
 11 11 
22 % within 
neuropathy 64.7% 47.8% 
Male 
 6 12 
18 % within 
neuropathy 35.3% 52.2% 
Total 
 
17 23 
40 % within 
neuropathy 100% 100% 
 
p= 0.289 not significant.  64.7% (11of 17) of the people with neuropathy 
were found to be females and 35.3% were (6 of 17) found to be males. The 
sex distribution difference of the two groups was not significant.   
 Socioeconomic status and neuropathy 
(Table 21) 
Socioeconomic 
status 
Number of 
patients 
Neuropathy Total Present absent 
Lower 
 
12 16 
28 % within 
neuropathy 70.6% 69.6% 
Middle 
 5 7 
12 % within 
neuropathy 29.4% 30.4% 
Total 
 17 23 
40 % within 
neuropathy 100% 100% 
 
  
 
 
p= 0.944, not significant. 70.6% (12 0f 17) patients with neuropathy 
belonged to lower socioeconomic status.  
No association was found between neuropathy and socioeconomic status 
There was no significant difference in the distribution of patients according 
to socioeconomic status among patients with neuropathy when compared 
to patients without neuropathy. 
 
 
 
 Smoking Vs  neuropathy 
Table-22 
Personal History 
- Smoking 
Number of 
patients 
Neuropathy Total Present Absent 
Yes 
 
5 3 
8 % within 
neuropathy 29.4% 13% 
No 
 12 20 
32 % within 
neuropathy 70.6%% 87% 
Total 
 17 23 
40 % within 
neuropathy 100% 100% 
 
p= 0.201, not significant. Among the patients with neuropathy 29.4%      
(5 of 17) were found to be smokers. There was no significant difference 
between the groups with regard to history of smoking. 
 
  
 
 
 Family history of diabetes  Vs neuropathy 
Table 23 
Family  History 
– Diabetes 
Mellitus 
Number of 
patients 
Neuropathy 
Total Present Absent 
Yes 
 
9 7 
16 % within 
neuropathy 52.9% 30.4% 
No 
 8 16 
24 % within 
neuropathy 47.1% 69.6% 
Total 
 17 23 
40 % within 
neuropathy 100% 100% 
 
p= 0.151, not significant.  There was no association found between family 
history of diabetes and neuropathy. 9 of 17 (52.9%) patients with 
neuropathy had family history of diabetes as against 7 of 23 without 
neuropathy. This difference was statistically not significant. 
 BMI    Vs   Neuropathy 
(Table 24) 
Neuropathy BMI(kg/m
2) 
No .of.patients Mean SD 
Present 17 26.65 2.737 
Absent 23 22.91 2.295 
 
p= 0.000 significant. The mean BMI of patients with neuropathy was 26 ± 
2.7 when compared to patients without neuropathy which was found to be 
  
 
 
22.91 ± 2.2 and the difference is significant.  BMI was found to be strongly 
associated with neuropathy.  
 
 Blood pressure  Vs  Neuropathy 
Table 25 
 
 Neuropathy Number of patients Mean SD 
Systolic  
BP 
Present 17 137.29 17.930 
Absent 23 126.52 12.391 
Diastolic 
BP 
Present 17 84.71 11.661 
Absent 23 77.04 8.798 
 
 
BP Systolic- p= 0.030 significant, BP Diastolic p= 0.023, significant 
 
A significant association was found between both systolic and diastolic   
Blood Pressure and neuropathy.  
The mean systolic BP of patients with neuropathy was 137±17mm of Hg 
compared to 126.52±12 among patients without neuropathy.  
The mean diastolic BP in patients with neuropathy was found to be 
84.7±11 when compared to 77.04±8.7 in patients without neuropathy. 
 
 
 
 
 
  
 
 
 FBS/PPBS/HbA1c   Vs  Neuropathy 
Table 26 
 
 Neuropathy Number of patients Mean SD 
FBS Present 17 144.94 21.058 
Absent 23 137.04 17.057 
PPBS Present 17 297.88 52.003 
Absent 23 254.74 44.518 
HbA1c Present 17 10.85 1.577 
Absent 23 8.52 1.230 
 
 
FBS; p= 0.198 not significant, PPBS; p= 0.008 Significant, 
HbA1c; p= 0.000 Significant. 
The mean FBS of patients with neuropathy was 144.9 ± 21.08mg/dl, 
whereas it was 137.04mg/dl among patients without neuropathy.  
The mean PPBS of patients with neuropathy was 297.88mg/dl whereas the 
mean PPBS of patients without neuropathy was 254.74mg/dl.  
The mean HbA1c of patients with neuropathy was 10.85 when compared to 
8.52 among patients without neuropathy. 
A significant association was found between post prandial blood sugar 
values and HbA1c with neuropathy in new diabetics. No significant 
association was found between fasting blood sugar values and neuropathy. 
 
 
 
 
  
 
 
GROUP 2 – IMPAIRED GLUCOSE TOLERANCE 
 
 Age   Vs Neuropathy 
Table 27 
Neuropathy Age (yrs) 
No .of. patients Mean SD 
Present 8 55.00 7.964 
Absent 32 42.50 6.965 
 
p= 0.000 Significant. 
 
The mean age of patients with neuropathy was found to be 55 ± 7.9yrs 
when compared to patients without neuropathy which was 42.50 ± 6.9yrs. 
The difference in the mean age between the two groups was found to be 
statistically significant. Age was found to be associated with neuropathy in 
patients with impaired glucose tolerance. 
 
 Sex   Vs  Neuropathy 
Table 28 
Sex Number of patients 
Neuropathy Total Present Absent 
Female 
 
3 20 
23 % within 
neuropathy 37.5% 62.5% 
Male 
 
5 12 
17 % within 
neuropathy 62.5% 37.5% 
total 
 
8 32 
40 % within 
neuropathy 100% 100% 
  
 
 
p= 0.201 not significant.  5(62.5%) patients among the 8 patients who had 
neuropathy were males where as females constituted 37.5% (3/8). This 
distribution not found to be significant when compared with patients 
without neuropathy. 
 
 
 Socioeconomic status and neuropathy. 
Table 29 
Socioeconomic 
status 
Number of 
patients 
Neuropathy Total Present Absent 
Lower 
 
6 19 
25 % within 
neuropathy 75% 59.4% 
Middle 
 
2 13 
15 % within 
neuropathy 25% 40.6% 
total 
 
8 32 
40 % within 
neuropathy 100% 100% 
 
p= 0.414, not significant. 75% (6 of 8) patients with neuropathy were from 
the low socioeconomic status.  
No association was found between neuropathy and socioeconomic status.  
There is no significant difference in the distribution of patients according 
to socioeconomic status among patients with neuropathy when compared 
to patients without neuropathy 
  
 
 
 Smoking  Vs   Neuropathy 
Table 30 
Personal 
History - 
Smoking 
Number of 
patients 
Neuropathy 
Total 
Present Absent 
Yes 
 
3 7 
10 % within 
neuropathy 37.5% 21.9% 
No 
 
5 25 
30 % within 
neuropathy 62.5% 78.1% 
Total 
 
8 32 
40 % within 
neuropathy 100% 100% 
 
p= 0.361, not significant. 3 patients (37.5%) among patients with 
neuropathy (8) were smokers. The difference between the two groups was 
not found to be statistically significant. No association was found between 
smoking and neuropathy. 
 
 BMI  Vs  Neuropathy 
Table 31 
Neuropathy BMI(kg/m
2) 
No .of.patients Mean SD 
Present 8 25.88 2.031 
Absent 32 22.44 2.435 
 
p = 0.001, significant. The mean BMI of patients with neuropathy was 
found to be 25.88±2.031 when compared to patients without neuropathy 
which was 22.44±2.43 .The difference in the mean BMI between the two 
  
 
 
groups was found to be statistically significant. BMI was found to be 
strongly associated with neuropathy. 
 Family history of diabetes and neuropathy 
Table 32 
Family  History 
– Diabetes 
Mellitus 
Number of 
patients 
Neuropathy 
Total Present Absent 
Yes 
 
4 14 
18 % within 
neuropathy 50% 43.7% 
No 
 
4 18 
22 % within 
neuropathy 50% 56.3% 
Total 
 
8 32 
40 % within 
neuropathy 100% 100% 
 
p= 0.751, not significant. 
 
50% (4 of 8) of patients with neuropathy had history of diabetes mellitus. 
Family history of diabetes was not found to be associated with diabetes 
mellitus. 
 Blood Pressure Vs  neuropathy 
Table 33 
 Neuropathy Number of patients Mean SD 
Systolic  BP Present 8 137.75 12.981 
Absent 32 124.25 15.581 
Diastolic BP Present 8 87.75 7.667 
Absent 32 77.94 9.374 
 
p= 0.030, Systolic BP. p= 0.009, Diastolic BP. - Significant 
  
 
 
 
The mean systolic BP found among patients with neuropathy was 
significantly higher than patients without neuropathy.137.75 vs 124.25. 
The mean diastolic BP among patients with neuropathy was found to be 
significantly higher than patients without neuropathy (87.75 vs 77.94). 
Both Systolic and Diastolic blood pressure was significantly associated 
with neuropathy 
 FBS/PPBS/HbA1c  Vs Neuropathy 
Table 34 
 Neuropathy Number of patients Mean SD 
FBS Present 8 87.13 8.043 Absent 32 79.22 8.257 
PPBS Present 8 182.25 9.020 Absent 32 164.63 10.317 
HbA1c Present 8 6.24 0.106 Absent 32 5.35 0.436 
 
FBS: p=0.020, PPBS: p= 0.000, HbA1c: p= 0.000, Significant. 
 
The mean FBS of patients with neuropathy (87.13) was significantly higher 
than patients without neuropathy (79.22). 
The mean PPBS of patients with neuropathy was 182.25 which is 
significantly higher than patients without neuropathy (164.63). 
The mean HbA1c of patients with neuropathy was significantly higher than 
patients without neuropathy (6.24 vs 5.35).   
  
 
 
DISCUSSION 
The prevalence of diabetic peripheral neuropathy according to the 
available literature varies from 8-43% in different populations. Partenan et 
al reported a prevalence of 8.3% among the newly diagnosed diabetic 
patients in his study which was conducted in Finland 47. The UKPDS study 
which has been a landmark study in diabetes has shown a prevalence of 
13% 30. Richelle. J. Koopman found in her study a prevalence of 21.5% 
among U.S. adults 136. Arindam dutta found a prevalence of 29% among 
the patients conducted in Manipur137. .Pradeepa and M. Rema et al in their 
Chennai Urban Rural Epidemiology study (CURES 55) found a prevalence 
of 19.5% among patients attending their outpatient clinic 52.The prevalence 
found in this study among patients attending our diabetology clinic in 
K.M.C was found to be 42.5%.  
The higher prevalence obtained in my study population may be 
because of the small study group as well as due to the inclusion of 
electrophysiological tests in the diagnosis of neuropathy. Most population 
based studies mainly rely on NSS and biothesiometry. There is a lack of 
uniformity among studies regarding the criteria for diagnosis, 
characteristics of study populations, patient selection, criteria for diagnosis 
of diabetes and sensitivity of methods used to diagnose diabetic 
neuropathy. However it clearly indicates that peripheral neuropathy is 
  
 
 
present in a significant percentage of diabetic people at time of diagnosis. 
Hence all people should be screened for peripheral neuropathy at diagnosis 
for optimal intervention. 
 Only two population based studies has evaluated the prevalence of 
peripheral neuropathy in IGT. First is the San Luis Valley study which had 
noted a prevalence of 11.2% for neuropathy among IGT and only 3.9% of 
normal subjects49. The7 MONICA/KORA Augsburg surveys conducted in 
Germany have noted a prevalence of 13% in the IGT group compared to 
7.3% among normal people 138. The studies reported from India have been 
mainly on the nerve conduction abnormalities in impaired glucose 
tolerance. However Ericsson et al139 and Sorensko JM, Kato M et al 140in 
their studies found no association with neuropathy and IGT.  Studies from 
India are lacking regarding the prevalence of neuropathy in impaired 
glucose tolerance. Vishwanathan et al has studied the nerve conduction 
abnormalities in different stages of glucose intolerance and has found that 
the mean MCV of impaired glucose tolerance patients were significantly 
lower than normal individuals 141. Sevki Sahin et al have found a 
prevalence of 16% for neuropathy among patients with impaired glucose 
tolerance in his study which was done in Turkey 142. 
 In our study we have found a prevalence of 20% among the IGT 
group. This is a major finding and points towards the need for detailed 
  
 
 
assessment of patients with impaired glucose tolerance on presentation. 
Also it shows the need for longitudinal studies in further evaluation of 
patients with impaired glucose tolerance 
Symptoms of neuropathy were found in 67.5% of new diabetics, in 
42.5% of IGT and in 20% of control group. 
Arindham Dutta et al found in his study that 32% had symptoms of 
neuropathy among newly diagnosed diabetics, J.M. Lehtinen, M Uustitupa 
et al found neuropathic symptoms in 1.5% of his study group 143.Zsuzsanna 
Putz M.D et al found neuropathic symptoms in 12.19% patients in their 
study on IGT patients144. 
Neuropathic signs were found in 17.5% of new diabetics, in 10% of IGT 
and 0% in control group. 
Arindam Dutta et al found 30% of his study group having 
neuropathic signs. J.M Lehtinen et al found neuropathic signs in 2.3% of 
patients, Klaus.P.Ratzmann found loss of reflexes in 13.6% of patients in 
his study 46. Zsuzsanna Putz M.D et al found a prevalence of impaired 
sensation in 12.5% of patients in her study on IGT patients. 
Abnormality in motor nerve conduction study was found in 37.5% of 
new diabetics, 35 % of patients with impaired glucose tolerance and in 
2.5% of control population 
  
 
 
Arindam Dutta et al found the prevalence of motor nerve conduction 
abnormality in his study in new diabetics to be 27%. Klaus .P.Ratzmann in 
his study found that the prevalence of motor nerve conduction abnormality 
was 15.7% among newly diagnosed diabetics. 
Eugenia Rota et al found in her study that motor nerve involvement 
was present in 60% of patients who were new diabetics145.Sevki Sahin et al 
found in their study on the nerve conduction abnormalities in IGT that 
motor nerve conduction abnormalities were found in 39.5% of patients. 
Sensory nerve conduction abnormalities were found in 40% of new 
diabetic group, in 30% of IGT group and in 0% of control population. 
 Eugenia Rota et al found the prevalence of sensory nerve 
abnormalities to be 56.4% among newly diagnosed diabetics. Sevki Sahin 
et al in their study found sensory nerve conduction abnormalities were 
found in 21% patients. 
RISK FACTOR ANALYSIS. 
Group 1 – NEW DIABETICS 
Age and Neuropathy-     The mean age of patients with neuropathy 
(46.4yrs), though was higher when compared with patients without 
neuropathy (43.57yrs)   it was not statistically significant. 
  
 
 
J M Lehtinen et al and Solomon O.Ugoya 146 et al found in their 
studies that age was not associated with neuropathy. However studies by 
Arindham Dutta et al and Young et al50 have shown significant association 
of age with neuropathy.  
Sex and Neuropathy - This study has not found association between either 
sex and neuropathy. Studies by Solomon et al and Arindham Dutta et al 3 
have also not found association between neuropathy and sex. 
Socioeconomic status and neuropathy - There was no significant 
association between socioeconomic status and neuropathy. 
Maria Eugenia Nina Mantilla has however found association with 
low socioeconomic status with neuropathy in their study among patients 
with diabetic neuropathy 147. 
Smoking and Neuropathy - Smoking was not found to be associated with 
prevalence of neuropathy among new diabetics. Partenan et al, J.M 
Lehtinen et al found no association with smoking in their study. However 
the findings by M.L Sands et al of the San Luis Valley study found 
association between current smoking and neuropathy 148. 
Family History of diabetes and Neuropathy - No association was found 
between family history of diabetes and prevalence of neuropathy in this 
  
 
 
study. Similar observation was made in the studies done by Solomon O 
Ugoya et al and M L Sands et al in their studies. 
BMI and Neuropathy - The mean BMI of patients with neuropathy 
(26.65) was found to be significantly higher than the patients without 
neuropathy (22.91). 
This is in agreement with the findings of J.M.Lehtinen et al, Cohen 
A et al 149 and Arindham dutta et al in their studies. However the 
association was not found to be there in the CURES-55 study done by R. 
Pradeepa, M. Hema et al. 
Blood Pressure and neuropathy – Both systolic and diastolic BP is found 
to be associated with neuropathy in this study. 
  Arindham Dutta et al found in their study that systolic and diastolic 
BP was higher in the neuropathy group but not statistically significant. 
Association of BP with neuropathy was found in studies done by Cohen et 
al, and Solomon O Ugoya in their studies. 
Fasting and Post prandial blood sugars and neuropathy - Though the 
mean fasting as well post prandial blood sugar values were higher among 
patients with neuropathy statistically significant association was found only 
between post prandial blood sugars and neuropathy. Similar findings were 
  
 
 
obtained by Ashok et al 150, Young et al, Arindham dutta et al and Junani 
Partenan et al in their studies. 
HbA1c and Neuropathy – HbA1c was found to be strongly associated 
with neuropathy among the new diabetics. Similar findings were obtained 
by J.Partenan et al, R.Predeepa et al, Solomon O Ugoya, Cohen A et al and 
M.L Sands et al. 
Group -2, IMPAIRED GLUCOSE TOLERANCE 
Age and Neuropathy- The mean age of patients with IGT were found to 
be significantly higher than the patients without neuropathy.  
Similar findings were obtained in the San Luis Valley studies and in 
the MONICA/KORA Augsburg studies. 
Sex and neuropathy -No association was found between either sex, and 
neuropathy.  
Vishawanathan et al has found in his study that male gender and 
nerve conduction abnormalities were related. San Luis Valley study also 
found that male gender and neuropathy were related. 
Socioeconomic status and neuropathy -No association was found 
between socioeconomic status and neuropathy. 
 
  
 
 
Family history of diabetes mellitus and neuropathy 
There was no association found between family history of diabetes and 
neuropathy. 
Smoking and Neuropathy - Singleton J.Robinson64 in their studies have 
found that neuropathy of impaired glucose tolerance and smoking were not 
related. No association was found between smoking and neuropathy in the 
group of patients with impaired glucose tolerance with regard to 
neuropathy in this study.  
BMI and neuropathy -The mean BMI of people with IGT and neuropathy 
was significantly higher than patients without neuropathy suggesting that 
BMI is associated with neuropathy in this group of patients. 
San Luis Valley Study however did not find any association between 
BMI and neuropathy. Vishwananthan et al also found that there was no 
association between BMI and nerve conduction abnormalities. The 
MONICA/KORA Augsburg studies found that the BMI was not associated 
with neuropathy. 
Blood Pressure and neuropathy – Both systolic and diastolic BP was 
found to be associated with neuropathy among patients with impaired 
glucose tolerance.                                         
  
 
 
Vishwanathan et al found in their study that only systolic BP was 
associated with nerve conduction abnormalities. 
FBS/PPBS/HbA1c 
Neuropathy was found to be associated with all the glycemic 
parameters namely fasting blood sugar values, post prandial blood sugar 
values as well as HbA1c. 
Vishwananthan et al have found a significant association between 
nerve conduction abnormalities and blood sugar values in their study. 
Similar results were also found in the San Luis valley Study. 
This study clearly shows that there is a significant prevalence of 
neuropathy in patients at time of diagnosis of neuropathy and even more 
importantly there is significant prevalence among patients with IGT. This 
suggests that neuropathy emerges very early in the natural history of 
diabetic patients, perhaps modulated further by the influence of genetic and 
environmental factors. The increased prevalence in both groups as well as 
association with blood sugar values and HbA1c suggest that 
hyperglycaemia is an important trigger to the cascade of events 
culminating in neuropathy.  
The role for other factors has to be further investigated as in most 
cases the available data is divided in its results. This study shows the need 
  
 
 
for more longitudinal and population based studies in diabetes and 
especially in impaired glucose tolerance to further clarify the increased 
prevalence of neuropathy and find the risk factors associated with it.    
ADA recommends that all patients with diabetes should be screened at 
diagnosis for the presence of neuropathy and also given advice regarding 
foot care. The increased prevalence in the impaired glucose tolerance 
group calls for early screening of these patients for neuropathy and 
initiate aggressive life style modifications in these patients as it has 
shown not only improve but reverse neuropathic changes in these people. If 
patients can be identified in their stage of impaired glucose tolerance and if 
screened and treated for complications , then the morbidity associated with 
diabetes can be remarkably reduced. We can ensure that diabetic patients 
have fitter, happier lives rather than painful deformed lives.     
This was a preliminary cross sectional study done to find the 
prevalence and risk factors of neuropathy in patients with diabetes and 
impaired glucose tolerance. The limitations of this study are that the study 
group was small and that the other risk factors for neuropathy like vitamin 
B12, hypothyroidism etc has not been ruled out in the study population. 
The increased prevalence of neuropathy in impaired glucose tolerance 
needs to be confirmed by a prospective long term study involving a large 
cohort of patients.                                   
  
 
 
SUMMARY 
 The aim of the present study was to find the prevalence of peripheral 
neuropathy in patients with newly diagnosed diabetes mellitus and in 
impaired glucose tolerance.  
 Forty patients were selected in each of the three groups randomly 
from among patients attending the department of diabtology. The 
presence of neuropathy was assessed with the help of nerve 
conduction studies as well as symptoms and signs for the same. The 
patients were also assessed regarding the various risk factors that 
might be associated with the disease.  
 The prevalence of diabetic neuropathy was found to be 42.5% 
among newly diagnosed diabetics and 20% among patients with 
impaired glucose tolerance. 
 The risk factors found to be associated with neuropathy among new 
diabetics were BMI, blood pressure (both systolic and diastolic), 
postprandial blood sugar levels as well as HbA1c. 
 The risk factors associated with the neuropathy of impaired glucose 
tolerance were age, BMI, systolic blood pressure, fasting and 
postprandial blood sugar values as well as HbA1c values. 
 This study calls for early screening of newly diagnosed and impaired 
glucose tolerance patients for the presence of peripheral neuropathy.                       
  
 
 
CONCLUSION 
 This study finds a significant prevalence of diabetic peripheral 
neuropathy in patients with newly detected diabetes mellitus and 
impaired glucose tolerance. 
 This study finds the association of other components of metabolic 
syndrome namely hypertension and BMI with neuropathy in both the 
study groups. This indicates that in these patients a multifaceted 
treatment approach giving equal weightage to drug therapy as well as 
life style modification should be advocated. 
 The study also highlights the importance of early screening of all 
patients with diabetes mellitus and even those in the stage of impaired 
glucose tolerance for complications, so that measures may be 
instituted to  prevent and halt the progression of complications of 
diabetes mellitus. 
  Effective measures to control the risk factors and early detection of 
diabetic neuropathy to prevent it from progressing are the key to 
maintain the quality of life in the diabetic population. This not only 
decreases the morbidity and mortality among the diabetic patients but 
also lessen the enormous financial burden faced while treating such 
complications, in the developing countries like India. 
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STUDY  OF PERIPHERAL NEUROPATHY IN NEWLY 
DETECTED DIABETES MELLITUS AND IN IMPAIRED 
GLUCOSE TOLERANCE 
 
Name:                                                                         Age:                                        
Sex:                        
Address:                                                                        Contact number: 
 
 
Socioeconomic status:                                                   Occupation: 
Educational Status: 
 
HISTORY 
Symptoms: Burning / tingling / cramps / gait disturbance / weakness 
/aching / numbess 
Joint pains/oral ulcers/rash 
Decreased urine output/hematuria/pedal edema/fascial 
puffiness  
                     Cough/hemoptysis/loss of appetite/loss of weight 
NSS 
PAST HISTORY 
H/o hypertension       Y / N          H/o PTB, ATT   Y / N                                
H/o CAD                Y / N            H/o STD      Y / N                                 
H/o Renal disease            Y / N            H/o hypothyroidism         Y / N     
H/o CVA                         Y / N   
 PERSONAL HISTORY 
Smoker         :                             Y / N                                  
Alcohol         :                              Y / N    
Drug abuse       :   Y / N ............. 
DIET                           :                          NV/V 
 
FAMILY HISTORY                                 
Hypertension                              :  
Diabetes Mellitus                        :     
Chronic Kidney Disease            : 
Neuropathy                                :  
TREATMENT HISTORY         : 
 EXAMINATION 
Height                                               - 
Weight                                               -               
BMI       - 
signs of hyperlipidemia              - 
BP                                                       - 
HR                                                      -      
Pallor                                                  - 
Pedal Edema                                       - 
Peripheral pulses                                 -                                            
Chest                                                    - 
CVS                                                     -   
P/A                                                       -    
CNS                                  Timed vibration                                   Pin Prick 
                                           Ankle jerk                                           
Temperature 
 
NDS 
 
INVESTIGATIONS 
 RBS 
FBS 
PPBS 
GTT 
HbA1c 
Nerve conduction study 
  
ABBREVIATIONS 
 
ARI                         Aldose reductase inhibitor 
ADA                       American Diabetic Association  
ATP                        Adenosine Triphosphate 
AGE                       Advanced glycation end product 
AT II                      Angiotensin II 
AD                         Anno Domini 
BP                          Blood Pressure 
BC                         Before Christ 
BMI                       Body Mass Index 
CTS                       Carpal Tunnel Syndrome 
CIDP                     Chronic inflammatory demyelinating neuropathy 
CURES                  Chennai Urban Rural Epidemiological study 
DM2                      Type 2 Diabetes Mellitus 
DCCT                    Diabetes Control and Complications Trial  
DPP                       Diabetes Prevention Programme Study 
EDTA                   Ethylene diamine Tetra Acetic Acid 
EP                          Electrophysiology 
ED                         Erectile Dysfunction 
FPG                       Fasting Blood Glucose 
FBS                       Fasting Blood Sugar 
PPBS                       Post Prandial Blood Sugar 
GDM                       Gestational Diabetes Mellitus 
GADPH                   Glyceraldehyde 3 phosphate dehydrogenase 
GAD                        Glutamic Acid Decarboxylase 
HPLC                       High Performance Liquid chromatography 
HbA1c                     Glycosylated hemoglobin 
IENF                        Intra Epidermal Nerve Fibre Density 
IGT                          Impaired Glucose Tolerance  
IFG                          Impaired fasting Glucose 
NGT                        Normal Glucose tolreance  
LGA                         Large for Gestational age 
LA                            Lipoic Acid 
MAPK                      Mitogen Activated Protein Kinase 
MNSI                       Michigan Neuropathy Screening Instrument 
MNCV                     Motor Nerve Conduction Velocity 
MONICA/KORA     Monitoring of Trends and Determinants in  
Cardiovascular   Disease Cooperative Research in 
the Region of Augsburg. 
NAD                       Nicotineamide Adenine Dinucleotide 
NSS                         Neuropathy Symptom Score 
NDS                        Neuropathy Disability Score 
NO                          Nitric Oxide 
NCV                        Nerve conduction Velocity 
OGTT                      Oral Glucose Tolerance test 
OHA                         Oral hypoglycaemic Drugs       
PKC                         Protein kinase C 
PDE                         Phosphodiesterase inhibitor  
PCOS                      Polycystic Ovarian Disease 
QST                        Quantitative sensory Testing 
ROS                         Reactive Oxygen Species 
RAGE                      Receptors for Advanced Glycation End Products 
RCT                          Ranomised Control Trial 
SNCV                       Sensory Nerve conduction Velocity 
SNAP                       Sensory Nerve Action Potential 
VPT                          Vibration Perception Threshold 
VEGF                       Vascular Endothelial Growth Factor 
UKPDS                     United Kingdom Diabetic Prospective Study 
WHO                         World Health Organisation   
&                               And 
mg/dl                         milligram per decilitre 
yrs                             years   
±                                plus or minus 
                          MASTER CHART ABBREVIATIONS 
 
Socio   -        Socioeconomic status 
NSS          -                Neuropathy Symptom Score 
HT               -                   Hypertension 
DM              -                   Diabetes Mellitus 
CAD          -                   Coronary Artery disease 
CVA            -                   Cerebrovascular Accident       
RENAL       -                   Renal Disease 
NV              -                   Nonvegetarian 
BMI             -                   Body mass index 
BP sys          -                  Systolic blood Pressure 
BP dias         -                   Diastolic blood Pressure 
NDS             -                   Neuropathy Disability Score 
FBS              -                  Fasting Blood Sugar 
PPBS            -                  Post Prandial Blood Sugar 
NCS             -                 Nerve conduction Study 
PTN             -                Tibial nerve 
MNCV         -          Motor nerve  Conduction Velocity 
CMAP          -          Compound Muscle Action Potential 
CPN             -           Common Peroneal Nerve 
SNCV          -             Sensory Nerve Conduction Velocity 
SNAP          -             Sensory Nerve Action potential 
ABN           -             Abnormality 
 
NEUROPATHY               0       -  Absent 
                                          1       -  Present 
SEX                                  M    -    Male 
                                         F       -  Female 
Age Group 
                                        1  =   20-30 
                                        2 =  31 - 40   
                                        3 =  41-50 
                                        4 = 51 and above 
Family History of Diabetes/Hypertension 
                                                  Y  =  Yes 
                                                   N =   No 
Socio economic status        Low      lower socioeconomic status 
                                            Mid     middle socioeconaomic status 
Smoking                                   Y =  Yes 
                                                  N = No 
Nerve conduction  ABN   -    Abnormality    Y= Yes 
                                                                       N =No   
Past history of HT/CAD/CVA/Renal disease/Smoking   – 
                                                                          Y = Yes 
                                                                          N = No 
Diet         Non vegetarian        -                        Y= Yes 
                                                                          N =No 
  
 
 
